ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
AbbVie Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$23.45 |
52 Week High | US$26.67 |
52 Week Low | US$19.45 |
Beta | 0.56 |
1 Month Change | -5.67% |
3 Month Change | -8.43% |
1 Year Change | 8.21% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -1.01% |
Recent News & Updates
Recent updates
Shareholder Returns
ABBV | CA Biotechs | CA Market | |
---|---|---|---|
7D | -0.8% | 1.7% | 3.1% |
1Y | 8.2% | -34.7% | 8.8% |
Return vs Industry: ABBV exceeded the Canadian Biotechs industry which returned -34.9% over the past year.
Return vs Market: ABBV matched the Canadian Market which returned 7.6% over the past year.
Price Volatility
ABBV volatility | |
---|---|
ABBV Average Weekly Movement | 3.0% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 8.7% |
10% most volatile stocks in CA Market | 17.8% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months.
Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
ABBV fundamental statistics | |
---|---|
Market cap | CA$394.17b |
Earnings (TTM) | CA$8.17b |
Revenue (TTM) | CA$74.71b |
47.6x
P/E Ratio5.2x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABBV income statement (TTM) | |
---|---|
Revenue | US$54.40b |
Cost of Revenue | US$16.85b |
Gross Profit | US$37.56b |
Other Expenses | US$31.60b |
Earnings | US$5.95b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 3.37 |
Gross Margin | 69.03% |
Net Profit Margin | 10.94% |
Debt/Equity Ratio | 924.1% |
How did ABBV perform over the long term?
See historical performance and comparison